Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.1% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) shares were down 1.1% on Monday . The company traded as low as $1,183.34 and last traded at $1,200.89. Approximately 2,315,010 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 3,231,220 shares. The stock had previously closed at $1,213.91.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: LLY continues to be viewed as a leader in the GLP-1 obesity and diabetes market, which has driven rapid revenue and earnings growth and keeps bullish investor sentiment intact.
• Positive Sentiment: Recent articles highlighted Lilly as a stock to watch amid renewed Nasdaq strength, reflecting continued market interest in the name.
• Positive Sentiment: Investor-focused coverage argued that buying Eli Lilly today could still set up long-term gains, pointing to its strong growth profile and defensive qualities.
• Positive Sentiment: Analyst sentiment remains constructive overall, with a “Moderate Buy” consensus and price targets clustered above current levels. MarketBeat LLY page
• Neutral Sentiment: LLY also drew heavy online search interest, suggesting the stock remains widely followed by traders and investors. Zacks article

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Bank of America increased their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,239.52.

Eli Lilly and Company Stock Performance

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.13 trillion, a price-to-earnings ratio of 42.66, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The stock has a 50-day simple moving average of $1,065.45 and a 200-day simple moving average of $1,027.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. Spire Wealth Management boosted its holdings in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares in the last quarter. Iams Wealth Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter worth approximately $754,000. Finally, Militia Capital Partners LP boosted its stake in Eli Lilly and Company by 333.3% in the 3rd quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock worth $1,984,000 after purchasing an additional 2,000 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.